Previous Close | $119.04 |
Intrinsic Value | $24.25 |
Upside potential | -80% |
Data is not available at this time.
Encompass Health Corporation operates as a leading provider of post-acute healthcare services in the U.S., specializing in inpatient rehabilitation and home health services. The company generates revenue primarily through patient care reimbursements from Medicare, Medicaid, and private insurers, leveraging its network of over 150 hospitals and home health agencies. Its vertically integrated model ensures continuity of care, positioning it as a critical player in the post-acute care continuum. Encompass Health differentiates itself through clinical excellence, evidenced by high patient satisfaction scores and industry-leading outcomes. The company benefits from favorable demographic trends, including an aging population and increasing demand for rehabilitation services. Its scale and operational efficiency provide a competitive edge in negotiating payer contracts and optimizing care delivery. The post-acute sector remains fragmented, allowing Encompass Health to capitalize on consolidation opportunities while maintaining a strong market position in key regions.
Encompass Health reported $5.37 billion in revenue for FY 2024, with net income of $455.7 million, reflecting a net margin of approximately 8.5%. The company’s operating cash flow of $1.0 billion underscores its ability to convert earnings into cash efficiently. Capital expenditures of $642.5 million indicate ongoing investments in facility upgrades and expansion, supporting long-term growth. Diluted EPS of $4.46 demonstrates solid profitability per share.
The company’s earnings power is driven by its high-margin rehabilitation services and disciplined cost management. Operating cash flow coverage of capital expenditures suggests sustainable reinvestment capacity. With a focus on optimizing bed utilization and payer mix, Encompass Health maintains strong returns on invested capital, though its leverage ratio warrants monitoring given $2.71 billion in total debt.
Encompass Health’s balance sheet shows $85.4 million in cash and equivalents against $2.71 billion in total debt, indicating moderate liquidity. The debt load is manageable given stable cash flows, but refinancing risks may arise in higher-rate environments. The company’s asset-light model in home health services helps maintain financial flexibility, though inpatient rehabilitation requires significant fixed investments.
Growth is supported by demographic tailwinds and strategic acquisitions, with revenue expanding steadily year-over-year. The company pays a dividend of $0.63 per share, offering a modest yield, reflecting a balanced approach to returning capital while funding expansion. Same-store admissions and pricing power remain key drivers of organic growth.
The market values Encompass Health at a premium relative to peers, reflecting its leadership in post-acute care and consistent execution. Investors likely price in mid-single-digit revenue growth and margin stability, though regulatory changes in reimbursement rates could impact valuations. The stock’s performance hinges on volume recovery and cost containment in a labor-sensitive industry.
Encompass Health’s integrated care model and scale provide durable advantages in a fragmented market. Near-term challenges include labor cost inflation and regulatory scrutiny, but long-term demand for rehabilitation services remains robust. Strategic investments in technology and outpatient care could further diversify revenue streams. The outlook is positive, assuming execution on operational efficiencies and disciplined M&A.
10-K filings, investor presentations
show cash flow forecast
Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
Revenue growth rate, % | NaN | |||||||||||||||||||||||||
Revenue, $ | NaN | |||||||||||||||||||||||||
Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
Total operating expenses, $m | NaN | |||||||||||||||||||||||||
Operating income, $m | NaN | |||||||||||||||||||||||||
EBITDA, $m | NaN | |||||||||||||||||||||||||
Interest expense (income), $m | NaN | |||||||||||||||||||||||||
Earnings before tax, $m | NaN | |||||||||||||||||||||||||
Tax expense, $m | NaN | |||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
Total assets, $m | NaN | |||||||||||||||||||||||||
Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
Average production assets, $m | NaN | |||||||||||||||||||||||||
Working capital, $m | NaN | |||||||||||||||||||||||||
Total debt, $m | NaN | |||||||||||||||||||||||||
Total liabilities, $m | NaN | |||||||||||||||||||||||||
Total equity, $m | NaN | |||||||||||||||||||||||||
Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
Funds from operations, $m | NaN | |||||||||||||||||||||||||
Change in working capital, $m | NaN | |||||||||||||||||||||||||
Cash from operations, $m | NaN | |||||||||||||||||||||||||
Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
New CAPEX, $m | NaN | |||||||||||||||||||||||||
Total CAPEX, $m | NaN | |||||||||||||||||||||||||
Free cash flow, $m | NaN | |||||||||||||||||||||||||
Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
Discount rate, % | NaN | |||||||||||||||||||||||||
PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
Current shareholders' claim on cash, % | NaN |